BCIQ Profiles

Company Profile Report
0423 Tyra ECP
BioCentury & Getty Images

Emerging Company Profile

Tyra: designing kinase inhibitors resistant to mutations

Emerging Company Profile: Tyra’s crystal structure generation platform accelerates design of kinase inhibitors resilient to resistance mutations

Tyra’s speedier X-ray crystal structure data generation is accelerating its R&D on kinase-targeting small molecules not susceptible to acquired cancer drug-resistance mutations.

Apr 23, 2021 | 6:10 PM GMT

Tyra is using its platform for rapidly generating X-ray crystal structures to accelerate the design of targeted small molecule kinase inhibitors that aren’t

Read the full 815 word article

How to gain access

Continue reading with a
two-week free trial.